Comparison of Seropositivity to Trichomonas vaginalis between Men with Prostatic Tumor and Normal Men.
Aged
Aged, 80 and over
Enzyme-Linked Immunosorbent Assay
Hospitals, University
Humans
Korea
/ epidemiology
Male
Middle Aged
Prostatic Neoplasms
/ complications
Republic of Korea
/ epidemiology
Seroepidemiologic Studies
Trichomonas Infections
/ epidemiology
Trichomonas vaginalis
/ immunology
Young Adult
Trichomonas vaginalis
benign prostatic hyperplasia
prostate cancer
seropositivity
Journal
The Korean journal of parasitology
ISSN: 1738-0006
Titre abrégé: Korean J Parasitol
Pays: Korea (South)
ID NLM: 9435800
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
01
01
2019
accepted:
10
02
2019
entrez:
7
3
2019
pubmed:
7
3
2019
medline:
13
4
2019
Statut:
ppublish
Résumé
Trichomoniasis is the most common curable sexually-transmitted infection. Most Trichomonas vaginalis-infected men are asymptomatic and can remain undiagnosed and untreated, and this has been thought to result in chronic persistent prostatic infection. Chronic inflammation is regarded as the major factor in the pathogenesis and progression of benign prostatic hyperplasia (BPH) and prostatic cancer (PCa). The aim of this study is to identify seropositivity to T. vaginalis in men with prostate tumors (BPH or PCa) visited to Hanyang University Hospital. A total of 183 men were enrolled between October 2013 and November 2014. They consisted of 139 with BPH (mean age: 64.0 ± 0.07) and 44 with prostate cancer (mean age: 73.3±0.18). We carried out ELISA to identify the seropositivity to T. vaginalis. Mixed lysate antigen extracted from 8 strains of T. vaginalis was used in the ELISA. Also 58 male outpatients visited to Health Promotion Center in Hanyang University Hospital were evaluated for comparing group. As a results, seropositivity to T. vaginalis in patients with prostatic diseases was 19.7% (BPH: 18.7%, PCa: 22.7%) and it was significantly higher than the 1.7% of the comparing healthy group (P = 0.001). Therefore, prostatic tumor showed higher seropositivity against T. vaginalis than normal men. As far as we know, this is the first report about seroprevalence in prostatic tumor in Korea.
Identifiants
pubmed: 30840795
pii: kjp.2019.57.1.21
doi: 10.3347/kjp.2019.57.1.21
pmc: PMC6409223
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-25Subventions
Organisme : Hanyang University
ID : 201200000002843
Références
Yonsei Med J. 1999 Feb;40(1):56-60
pubmed: 10198607
Infect Dis Obstet Gynecol. 2000;8(5-6):248-57
pubmed: 11220487
Int J Antimicrob Agents. 2004 Sep;24 Suppl 1:S53-6
pubmed: 15364308
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):939-45
pubmed: 16702374
J Clin Microbiol. 2006 Nov;44(11):3994-9
pubmed: 16971646
Clin Infect Dis. 2007 Jan 1;44(1):13-22
pubmed: 17143809
J Natl Cancer Inst. 2009 Oct 21;101(20):1406-11
pubmed: 19741211
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Med Microbiol Immunol. 2012 Feb;201(1):113-6
pubmed: 21660495
Korean J Parasitol. 2012 Jun;50(2):157-9
pubmed: 22711929
PLoS Pathog. 2012;8(8):e1002801
pubmed: 22912571
Arch Pathol Lab Med. 1986 May;110(5):430-2
pubmed: 2421689
Prostate. 2014 Apr;74(4):441-9
pubmed: 24339030
Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):847-56
pubmed: 24748218
Korean J Parasitol. 2014 Oct;52(5):551-5
pubmed: 25352707
Parasitol Int. 2015 Oct;64(5):405-7
pubmed: 26072305
Prostate. 2016 May;76(7):620-3
pubmed: 26818005
Parasite Immunol. 2016 Apr;38(4):218-27
pubmed: 26832322
Prostate. 2016 Nov;76(15):1431-44
pubmed: 27325623
Diagn Cytopathol. 1987 Sep;3(3):227-9
pubmed: 3311667